AbCellera Biologics Inc. (ABCL) DCF Valuation

AbCellera Biologics Inc. (ABCL) DCF Valuation
  • ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
  • ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
  • ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
  • ✓ Aucune Expertise N'Est Requise; Facile À Suivre

AbCellera Biologics Inc. (ABCL) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

As an investor or analyst, the AbCellera Biologics Inc. (ABCL) DCF Calculator is your go-to resource for accurate valuation. Featuring real data from AbCellera, you can adjust forecasts and observe the effects in real time.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue 11.6 233.2 375.2 485.4 38.0 47.4 59.0 73.4 91.5 113.9
Revenue Growth, % 0 1907.96 60.92 29.38 -92.17 24.53 24.53 24.53 24.53 24.53
EBITDA -.4 169.6 241.6 272.2 -192.2 8.5 10.6 13.2 16.4 20.5
EBITDA, % -3.42 72.75 64.4 56.07 -505.35 17.96 17.96 17.96 17.96 17.96
Depreciation 1.6 5.3 17.3 33.1 30.9 10.3 12.8 16.0 19.9 24.8
Depreciation, % 13.81 2.26 4.6 6.82 81.25 21.75 21.75 21.75 21.75 21.75
EBIT -2.0 164.3 224.4 239.1 -223.1 5.9 7.3 9.2 11.4 14.2
EBIT, % -17.24 70.49 59.8 49.26 -586.59 12.46 12.46 12.46 12.46 12.46
Total Cash 7.6 594.1 723.0 886.5 760.6 44.0 54.8 68.3 85.1 105.9
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables 2.1 213.2 160.6 38.6 64.4
Account Receivables, % 18.29 91.46 42.8 7.95 169.31
Inventories .2 1.4 1.7 1.5 1.1 .5 .7 .8 1.0 1.3
Inventories, % 1.4 0.60389 0.44563 0.3156 2.91 1.14 1.14 1.14 1.14 1.14
Accounts Payable 1.6 7.3 14.9 14.8 25.5 8.7 10.8 13.4 16.7 20.8
Accounts Payable, % 14.16 3.14 3.98 3.05 67.08 18.28 18.28 18.28 18.28 18.28
Capital Expenditure -4.0 -14.7 -58.5 -72.7 -77.5 -16.2 -20.2 -25.2 -31.3 -39.0
Capital Expenditure, % -34.42 -6.29 -15.58 -14.97 -203.83 -34.25 -34.25 -34.25 -34.25 -34.25
Tax Rate, % 15.88 15.88 15.88 15.88 15.88 15.88 15.88 15.88 15.88 15.88
EBITAT -2.2 123.8 157.1 158.5 -187.6 4.7 5.8 7.2 9.0 11.2
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -5.2 -92.3 175.9 241.0 -248.9 22.2 -5.6 -7.0 -8.7 -10.8
WACC, % 5.97 5.88 5.86 5.85 5.91 5.89 5.89 5.89 5.89 5.89
PV UFCF
SUM PV UFCF -5.0
Long Term Growth Rate, % 4.00
Free cash flow (T + 1) -11
Terminal Value -596
Present Terminal Value -447
Enterprise Value -452
Net Debt -56
Equity Value -396
Diluted Shares Outstanding, MM 289
Equity Value Per Share -1.37

What You Will Get

  • Pre-Filled Financial Model: AbCellera’s actual data allows for accurate DCF valuation.
  • Full Forecast Control: Modify revenue growth, profit margins, WACC, and other essential drivers.
  • Instant Calculations: Real-time updates ensure you see the impact of your changes immediately.
  • Investor-Ready Template: A polished Excel file crafted for high-quality valuation purposes.
  • Customizable and Reusable: Designed for adaptability, enabling repeated application for in-depth forecasts.

Key Features

  • Accurate Financial Data for AbCellera: Access reliable pre-loaded historical data and future forecasts specific to AbCellera Biologics Inc. (ABCL).
  • Adjustable Forecast Parameters: Modify highlighted cells such as WACC, growth rates, and profit margins to suit your analysis.
  • Automated Calculations: Instant updates to DCF, Net Present Value (NPV), and cash flow metrics.
  • User-Friendly Dashboard: Clear charts and summaries for easy visualization of your valuation outcomes.
  • Designed for All Levels: An intuitive layout tailored for investors, CFOs, and consultants alike.

How It Works

  1. Download the Template: Gain immediate access to the Excel-based ABCL DCF Calculator.
  2. Input Your Assumptions: Modify the yellow-highlighted cells for growth rates, WACC, margins, and additional parameters.
  3. Instant Calculations: The model automatically refreshes AbCellera’s intrinsic value.
  4. Test Scenarios: Experiment with various assumptions to assess potential valuation shifts.
  5. Analyze and Decide: Utilize the results to inform your investment or financial analysis.

Why Choose This Calculator for AbCellera Biologics Inc. (ABCL)?

  • User-Friendly Interface: Tailored for both novice users and seasoned professionals.
  • Customizable Inputs: Adjust assumptions effortlessly to suit your financial analysis.
  • Real-Time Valuation: Monitor immediate fluctuations in AbCellera’s valuation as you tweak the parameters.
  • Preloaded Financials: Comes equipped with AbCellera’s latest financial data for swift evaluations.
  • Relied Upon by Experts: A go-to tool for investors and analysts seeking to make educated choices.

Who Should Use This Product?

  • Biotech Investors: Develop comprehensive and accurate valuation models for assessing AbCellera Biologics Inc. (ABCL).
  • Corporate Strategy Teams: Evaluate valuation scenarios to inform strategic decisions within the biotech sector.
  • Consultants and Advisors: Deliver precise valuation insights for clients interested in AbCellera Biologics Inc. (ABCL).
  • Students and Educators: Utilize real-time data to practice and teach financial modeling in biotechnology.
  • Healthcare Enthusiasts: Gain insights into how biotech companies like AbCellera Biologics Inc. (ABCL) are valued in the market.

What the Template Contains

  • Preloaded ABCL Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
  • DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
  • Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
  • Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
  • Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
  • Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.

No products were found matching.